Treatment of Metastatic Renal Cell Carcinoma With Nephrectomy, Interleukin-2 and Cytokine-Primed or CD8(+) Selected Tumor Infiltrating Lymphocytes from Primary Tumor

Autor:	Arie S. Belldegrun, Nancy Moldawer, Barbara J. Gitlitz, William Pierce, Jean B. deKernion, Cho Lea Tso, Randir Kaboo, Robert A. Figlin
Rok vydání:	1997
Předmět:	Oncology medicine.medical_specialty Pathology Performance status business.industry Tumor-infiltrating lymphocytes Urology medicine.medical_treatment Immunotherapy medicine.disease Primary tumor Nephrectomy Metastasis Renal cell carcinoma Internal medicine Carcinoma Medicine business
Zdroj:	Journal of Urology. 158:740-745
ISSN:	1527-3792 0022-5347
DOI:	10.1016/s0022-5347(01)64304-0
Popis:	Purpose: Metastatic renal cell carcinoma is a disease with a mean survival of 6 to 10 months. Interleukin-2 (IL-2), the only approved therapy for metastatic renal cell carcinoma, is associated with a 14% response rate and durable remissions in some patients with high performance status. We performed a series of trials of IL-2 plus tumor infiltrating lymphocyte cell therapy and report the clinical results from 62 patients enrolled in these trials.Materials and Methods: Patients were eligible if they had metastatic renal cell carcinoma with the primary tumor in place and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were treated with cytokines before nephrectomy and preparation of cytokine primed tumor infiltrating lymphocytes or CD8(-) tumor infiltrating lymphocytes were isolated for infusion into patients. Of 62 patients enrolled 55 were treated with tumor infiltrating lymphocytes and IL-2, and were evaluable for toxicity, response and survival.Results: There were no...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::62389046a1817d7d0c16170364c4775f https://doi.org/10.1016/s0022-5347(01)64304-0 Zobrazit plný text záznamu